CHMP Positive on Bayer's Xarelto - Analyst Blog

By
A A A

Bayer 's ( BAYRY ) HealthCare segment recently received a positive recommendation from the European Committee for Medicinal Products for Human Use (CHMP) for Xarelto (rivaroxaban) in combination with standard antiplatelet therapy.

Bayer is looking to get Xarelto's label expanded for the prevention of atherothrombotic events (myocardial infarction, cardiovascular death or stroke) after an acute coronary syndrome (ACS) in adults having elevated cardiac biomarkers.

A final decision from the European Commission on the approval of the new indication of Xarelto is expected soon. We note that though the European Commission is not bound to follow the CHMP's decision, it generally does so.

Xarelto was studied in the phase III ATLAS ACS 2-TIMI 51 study. Results from the study showed that Xarelto along with standard antiplatelet therapy significantly reduced cardiovascular death, myocardial infarction or stroke in patients after an ACS in comparison to those who received standard antiplatelet therapy alone.

Xarelto is marketed by Johnson & Johnson ( JNJ ) in the US and by Bayer outside the US.

We note that Xarelto is already approved for several indications in the US including stroke prevention in nonvalvular atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism (PE) and reducing the risk of recurrent DVT and PE. The drug performed impressively last year. In 2012, Xarelto sales increased 265.9% year over year to €322 million (approximately $414.1 million).

Earlier this month, Bayer and Johnson & Johnson received a huge setback with the US Food and Drug Administration (FDA) issuing a second complete response letter (CRL) for the supplemental New Drug Application (sNDA) for Xarelto (2.5 mg twice daily) for the reduction of the risk of secondary cardiovascular events in patients suffering from ACS.

A second CRL from the US regulatory body is a huge disappointment for the company. Bayer, a large cap pharma company, currently carries a Zacks Rank #4 (Sell). Meanwhile other large cap pharma stocks such as Novo Nordisk ( NVO ) and AbbVie Inc. ( ABBV ) are better positioned carrying a Zacks Rank #2 (Buy).



ABBVIE INC (ABBV): Free Stock Analysis Report

BAYER A G -ADR (BAYRY): Free Stock Analysis Report

JOHNSON & JOHNS (JNJ): Free Stock Analysis Report

NOVO-NORDISK AS (NVO): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: ABBV , BAYRY , CHMP , CRL , JNJ

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

67,310,517
  • $100.53 ▲ 1.38%
50,893,843
  • $8.02 ▲ 2.56%
48,783,882
  • $10.25 ▲ 3.85%
43,859,280
  • $5.39 ▼ 4.09%
41,392,452
    $15.45 unch
31,440,620
  • $8.09 ▲ 3.45%
30,705,588
  • $3.11 ▲ 0.97%
28,829,509
  • $3.87 ▲ 19.44%
As of 8/19/2014, 04:03 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com